Acute Myeloid Leukemia | CHOP Research Institute

Acute Myeloid Leukemia

Published on
Sep 8, 2023
Sarah K. Tasian, MD, received a $1 million grant to further her research into a novel immunotherapy for high-risk pediatric leukemias.
Published on
Jul 7, 2023
See highlights from the Third Annual Lymphatic Disorder Conference and Cellicon Valley ’23, and more in this week’s research news roundup.
Published on
Jun 22, 2023
Wei Tong, PhD, and colleagues found a protein interaction that appears to be a driver of hematologic malignancies.
Published on
Dec 9, 2022
This week's news roundup features an outstanding science award, Highly Cited Researchers, and STAT Wunderkinds, along with new research about cancer risk with birth defects, epilepsy, and acute myeloid leukemia.
Published on
Sep 19, 2022
CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).

Published on
May 19, 2021
CHOP Researchers find the novel mechanistic link by which MNI causes acute myeloid leukemia.

Research in the Tasian Laboratory focuses on the bench-to-bedside investigation of precision medicine therapies for high-risk childhood leukemias.

This phase 1/2 study will determine the safety, feasibility, and efficacy of CD33 CART cells following lymphodepleting chemotherapy in patients with acute myeloid leukemia (AML).

The Aplenc Lab investigates ways to improve the outcomes of children with cancer, particularly acute myeloid leukemia, through translational studies, patient-centered outcomes research, and with clinical epidemiology studies.